Logo Logo
Switch Language to German

Kanellakis, Nikolaos; Asciak, Rachelle; Hamid, Megat Abd; Yao, Xuan; McCole, Mark; McGowan, Simon; Seraia, Elena; Hatch, Stephanie; Hallifax, Rob J.; Mercer, Rachel M.; Bedawi, Eihab O.; Jones, Stephanie; Verrill, Clare; Dobson, Melissa; George, Vineeth; Stathopoulos, Georgios T.; Peng, Yanchun; Ebner, Daniel; Dong, Tao; Rahman, Najib M. and Psallidas, Ioannis (2020): Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments. In: Thorax, Vol. 75, No. 11: pp. 1004-1008 [PDF, 1MB]

[thumbnail of 1004.full.pdf]
Download (1MB)


Malignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpatient heterogeneity. A subset of the cells were subjected to high-throughput drug screening and coculture assays with cancer-specific cytotoxic T cells and showed diverse responses. Some of the biphasic MPM cells were capable of processing and presenting the neoantigen SSX-2 endogenously. In conclusion, patient-derived MPM cell cultures are a promising and faithful ex vivo model of MPM.

Actions (login required)

View Item View Item